|Other Names||Thioredoxin-like protein 1, 32 kDa thioredoxin-related protein, TXNL1, TRP32, TXL, TXNL|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1336a was selected from the N-term region of human TrxL. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||TRP32, TXL, TXNL|
|Function||Active thioredoxin with a redox potential of about -250 mV.|
|Cellular Location||Cytoplasm. Nucleus. Note=At least 85% of the cellular TXNL1 is proteasome-associated|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Thioredoxins are a group of small redox active proteins possessing a conserved active site sequence. TrxL (Thioredoxin like protein 1) has 2 distinct domains: an N terminal domain, which is 43% identical to human TXN, and a C terminal domain, which shows no homology to other proteins in the sequence databases. The active site sequence, located within the N terminal domain, is that of a thioredoxin like protein; compared to the active site sequence of TXN, it has a single amino acid substitution. Unlike other thioredoxin like proteins, TrxL does not serve as a substrate for thioredoxin reductase in an insulin assay.
Miranda-Vizuete, A., et al., DNA Seq. 10(6):419-424 (2000).Lee, K.K., et al., J. Biol. Chem. 273(30):19160-19166 (1998).Miranda-Vizuete, A., et al., Biochem. Biophys. Res. Commun. 243(1):284-288 (1998).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.